OR WAIT null SECS
Beckman Coulter Life Sciences and IncellDx have announced a collaboration aimed at creating awareness for the oncology assays on the cytometry platform for European customers.
Beckman Coulter Life Sciences and IncellDx have announced, in a Nov. 20, 2019 press release, a collaboration aimed at creating awareness for the oncology assays on the cytometry platform for European customers.
Four cancer detection reagents were developed by IncellDx using Beckman Coulter’s instruments, under the partnership. The assays relate to lung and bladder cancers as well as human papillomavirus (HPV) cancers affecting the head, neck, and cervix.
“The new partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification,” said Mario Koksch, vice-president and general manager, Beckman Coulter Life Sciences Cytometry Business Unit, in the press release. “In addition, the oncology menu of IncellDx adds a new dimension to Beckman Coulter instruments, such as the CytoFLEX Series, which positions our technology at the forefront of clinical research.”
Bruce Patterson, CEO and founder of IncellDx, commented, “In cancer research, it is essential to carry out quantification at the single cell level. Adding our single cell, simultaneous protein, mRNA, and cell cycle/DNA content assays to the technology behind Beckman Coulter Life Sciences flow cytometry instruments will open up a new era in understanding cancer biology.”
Source: Beckman Coulter